Morgan Stanley lessened its holdings in Eyepoint Pharmaceuticals Inc (NASDAQ:EYPT) by 14.9% during the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 275,124 shares of the company’s stock after selling 48,065 shares during the period. Morgan Stanley owned approximately 0.26% of Eyepoint Pharmaceuticals worth $451,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors have also made changes to their positions in the company. Strs Ohio bought a new stake in shares of Eyepoint Pharmaceuticals in the 2nd quarter worth approximately $27,000. Wells Fargo & Company MN raised its stake in shares of Eyepoint Pharmaceuticals by 90.0% in the second quarter. Wells Fargo & Company MN now owns 96,945 shares of the company’s stock valued at $159,000 after buying an additional 45,922 shares during the period. JPMorgan Chase & Co. bought a new stake in shares of Eyepoint Pharmaceuticals in the second quarter valued at $28,000. Charles Schwab Investment Management Inc. raised its stake in shares of Eyepoint Pharmaceuticals by 882.3% in the second quarter. Charles Schwab Investment Management Inc. now owns 143,409 shares of the company’s stock valued at $236,000 after buying an additional 128,809 shares during the period. Finally, Bank of New York Mellon Corp raised its stake in shares of Eyepoint Pharmaceuticals by 225.7% in the second quarter. Bank of New York Mellon Corp now owns 149,870 shares of the company’s stock valued at $245,000 after buying an additional 103,857 shares during the period. Hedge funds and other institutional investors own 57.37% of the company’s stock.
Shares of EYPT traded up $0.08 during midday trading on Tuesday, reaching $1.36. The stock had a trading volume of 725 shares, compared to its average volume of 682,678. The company’s 50-day moving average is $2.10 and its 200 day moving average is $1.71. Eyepoint Pharmaceuticals Inc has a 12-month low of $1.19 and a 12-month high of $2.82. The company has a current ratio of 4.54, a quick ratio of 4.29 and a debt-to-equity ratio of 3.12. The company has a market capitalization of $156.77 million, a price-to-earnings ratio of -2.21 and a beta of 1.79.
Several equities analysts have recently weighed in on EYPT shares. Guggenheim assumed coverage on Eyepoint Pharmaceuticals in a research report on Thursday, September 12th. They issued a “buy” rating and a $4.00 price target for the company. ValuEngine cut Eyepoint Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday. B. Riley cut their price objective on Eyepoint Pharmaceuticals from $5.75 to $4.00 and set a “buy” rating for the company in a report on Tuesday, September 24th. Laidlaw started coverage on Eyepoint Pharmaceuticals in a report on Monday, November 4th. They issued a “buy” rating and a $5.00 price objective for the company. Finally, Zacks Investment Research upgraded Eyepoint Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday. Three research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The company currently has an average rating of “Buy” and a consensus target price of $3.95.
Eyepoint Pharmaceuticals Profile
EyePoint Pharmaceuticals, Inc, a specialty biopharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States and Europe. It provides ILUVIEN for the treatment of diabetic macular edema; YUTIQ, a non-erodible fluocinolone acetonide insert for the treatment of non-infectious posterior uveitis (NIPU) that is in the Phase III clinical trials; and Retisert (fluocinolone acetonide intravitreal implant), a sustained-release implant for the treatment of posterior segment uveitis.
Featured Story: What do investors mean by earnings per share?
Receive News & Ratings for Eyepoint Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eyepoint Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.